Capricor Therapeutics (CAPR) Long-Term Debt Issuances (2013 - 2018)
Capricor Therapeutics (CAPR) posted quarterly Long-Term Debt Issuances of -$139140.0 for Q2 2018, down 155.66% year-over-year from $250000.0 in Q2 2017, and down 200.0% quarter-over-quarter from $139140.0 in Q1 2018.
Capricor Therapeutics (CAPR) Long-Term Debt Issuances (2013 - 2018) Analysis & Trends
Capricor Therapeutics' Long-Term Debt Issuances history runs 5 years deep, the most recent figure standing at -$139140.0 for Q2 2018.
- In Q2 2018, Long-Term Debt Issuances fell 155.66% year-over-year to -$139140.0; the TTM figure through Sep 2019 stood at -$139140.0 (down 155.66% YoY), while the FY2020 annual figure was $318160.0, changed N/A from the prior year.
- Long-Term Debt Issuances for Q2 2018 stood at -$139140.0, down from $139140.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $2.0 million in Q2 2016, with the low at -$139140.0 in Q2 2018.
- The 4-year median for Long-Term Debt Issuances is $250000.0 (2017), against an average of $576417.7.
- The sharpest annual moves came in 2014 and 2018: Long-Term Debt Issuances tumbled 83.24% in 2014, then tumbled 155.66% in 2018.
- Capricor Therapeutics' Long-Term Debt Issuances stood at -$6667.0 in 2014, then jumped by 26348.69% to $1.8 million in 2016, then sank by 85.71% to $250000.0 in 2017, then sank by 155.66% to -$139140.0 in 2018.
- Business Quant data shows CAPR's Long-Term Debt Issuances at -$139140.0 in Q2 2018, $139140.0 in Q1 2018, and $250000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | -139,140.00 |
| Jun 30, 2018 | -139,140.00 |
| Mar 31, 2018 | 139,140.00 |
| Mar 31, 2018 | 139,140.00 |
| Dec 31, 2017 | 250,000.00 |
| Dec 31, 2017 | 250,000.00 |
| Jun 30, 2017 | 250,000.00 |
| Jun 30, 2017 | 250,000.00 |
| Sep 30, 2016 | 1.75 Mn |
| Sep 30, 2016 | 1.75 Mn |
| Jun 30, 2016 | 2.00 Mn |
| Jun 30, 2016 | 2.00 Mn |
| Mar 31, 2016 | 1.00 Mn |
| Mar 31, 2016 | 1.00 Mn |
| Dec 31, 2014 | -6,667.00 |
| Dec 31, 2014 | -6,667.00 |
| Sep 30, 2014 | 514,177.00 |
| Sep 30, 2014 | 514,177.00 |
| Jun 30, 2014 | 6,667.00 |
| Jun 30, 2014 | 6,667.00 |